赵晨, 吴超群, 孙健. 食管鳞癌放疗后复发再治疗的近期疗效观察[J]. 中国肿瘤临床, 2006, 33(16): 944-947.
引用本文: 赵晨, 吴超群, 孙健. 食管鳞癌放疗后复发再治疗的近期疗效观察[J]. 中国肿瘤临床, 2006, 33(16): 944-947.
shu
Zhao Chen, Wu Chaoqun, Sun Jian. The Observation of the Short-term Effects of Chemo-radiotherapy for Postradiotherapeutic Relapse of Esophagus Squamous Cell Cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 33(16): 944-947.
Citation: Zhao Chen, Wu Chaoqun, Sun Jian. The Observation of the Short-term Effects of Chemo-radiotherapy for Postradiotherapeutic Relapse of Esophagus Squamous Cell Cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 33(16): 944-947.
shu

食管鳞癌放疗后复发再治疗的近期疗效观察

The Observation of the Short-term Effects of Chemo-radiotherapy for Postradiotherapeutic Relapse of Esophagus Squamous Cell Cancer

    摘要
  • 摘要: 目的 :观察食管鳞癌放疗后复发再治疗的近期疗效。 方法 :65例经病理证实复发接受并完成治疗。32例1年内复发者为A组,33例1年后复发者为B组。均先行化疗两个周期。NP方案:34例,A组16例,B组18例,NVB25mg·m-2ivdrip第1、8天,DDP30mg·m-2ivdrip第1～3天,常规水化。DF方案:31例,A组16例,B组15例,DDP同前,CF200mg,FT-2071000mgivdrip每日1次,连用5天。均21天一个周期。两个周期后放疗。B组33例,先予6MV-X线,适形照射DT30Gy·3周-1,再行后装治疗DT5Gy(次·周)-1,连续4～6周。A组32例直接作后装治疗,方法同前。19例锁骨上淋巴结转移者,局部照射DT60～70Gy。 结果 :总有效率41.5%。A组再治疗有效率28.1%低于B组54.5%。NP有效率44.1%优于DF38.7%。全组1、2年生存率分别为27.7%、15.3%;A与B组分别为15.6%、3.1%与39.4%、27.3%;NP与DF分别为32.3%、20.6%与22.6%、9.7%。A组副作用高于B组。 结论 :食管癌放疗后复发,只要条件允许,不应轻易放弃治疗,特别是1年后复发者。在放疗前建议使用NP方案。长期疗效有待观察。

     

    Abstract: Objective : To observe the short-term effects of chemo-radiotherapy for postradiotherapeutic relapse of esophageal squamous cell cancer. Methods : A total of 65 cases with relapse of esophageal squamous cell cancer were substantiated by pathologic examination and were divided into two groups: 32 cases in group A, with relapse within 1 year after treatment and other 33 in group B with relapse 1 year after treatment. Both groups received two cycles of chemotherapy in advance. The NP protocol (NVB 25mg/m2 IV drip D1, 8; DDP 30mg/m2 IV drip D1-3) was employed in 34 cases (16 from group A and 18 from group B), and 31 cases (16 of group A and 15 of group B) received DF protocol (DDP 30mg/m2 IV drip D1-3; CF 200mg, FT-207 1000mg IV drip D1-5). Radiotherapy was delivered after two cycle of chemotherapy. Results : The total effective rate (TER) was 41.5%. The effective rate of group B was 54.5%, which is superior to that of group A (28.1%). The TER of NP protocol was 44.1%, which was superior to that of DF protocol (38.7%). The 1 and 2-year overall survival of the two groups was 27.7% and 15.3% respectively. The 1 and 2-year survivals in group A were 15.6% and 3.1%, whereas in group B they were 39.4% and 27.3%. The 1 and 2-year survivals for NP-protocol chemotherapy group were 32.3% and 20.6%, and in the group with DF protocol they were 22.6% and 9.7%. The side effect in group B was lower than in group A. Conclusion : The postradiotherapeutic relapse of esophageal squamous cell cancer may probably be retreated in case some conditions are satisfied, especially with relapse occurring one year after treatment. NP protocol chemotherapy is recommended before radiotherapy. More observations should be done for evaluation of the long-term effectiveness of the chemoradiotherapy.

     

    • HTML全文
    • 参考文献(11)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回